Index RUT P/E - EPS (ttm) - Insider Own 41.29% Shs Outstand 34.20M Perf Week -0.44%
Market Cap 161.32M Forward P/E - EPS next Y - Insider Trans 21.67% Shs Float 21.05M Perf Month -11.94%
Income - PEG - EPS next Q -0.83 Inst Own 31.08% Short Float 8.32% Perf Quarter -75.17%
Sales - P/S - EPS this Y - Inst Trans 23.88% Short Ratio 2.30 Perf Half Y -
Book/sh 9.17 P/B 0.49 EPS next Y - ROA - Short Interest 1.75M Perf Year -
Cash/sh 9.33 P/C 0.48 EPS next 5Y - ROE - 52W Range 3.85 - 26.62 Perf YTD -22.28%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -83.10% Beta -
Dividend TTM - Quick Ratio 17.63 Sales past 5Y 0.00% Gross Margin - 52W Low 16.88% ATR (14) 0.38
Dividend Ex-Date - Current Ratio 17.63 EPS Y/Y TTM - Oper. Margin - RSI (14) 39.38 Volatility 6.13% 6.47%
Employees - Debt/Eq 0.03 Sales Y/Y TTM - Profit Margin - Recom 3.67 Target Price 6.33
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q -36.08% Payout - Rel Volume 0.09 Prev Close 4.40
Sales Surprise - EPS Surprise -889.95% Sales Q/Q - Earnings Nov 07 AMC Avg Volume 762.31K Price 4.50
SMA20 -3.54% SMA50 -8.95% SMA200 -65.81% Trades
Volume 70,401 Change 2.27%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-10-24 Downgrade Morgan Stanley
Overweight → Underweight
$40 → $5
Dec-09-24 Downgrade Jefferies
Buy → Hold
$42 → $7
Dec-09-24 Downgrade Citigroup
Buy → Neutral
$45 → $7
Oct-21-24 Initiated Morgan Stanley
Overweight
$40
Oct-21-24 Initiated Jefferies
Buy
$42
Oct-21-24 Initiated Citigroup
Buy
$45
Feb-20-25 04:30PM
10:36AM
Feb-16-25 07:18AM
Feb-14-25 05:45AM
Feb-13-25 08:42AM
05:45AM
Loading…
Feb-07-25 05:45AM
Jan-30-25 09:01AM
Jan-29-25 05:39AM
Jan-28-25 07:27PM
09:00AM
Jan-24-25 05:45AM
Jan-22-25 03:00AM
Jan-21-25 05:45AM
Jan-18-25 03:07AM
Jan-06-25 09:00PM
12:51PM
Loading…
Jan-03-25 12:51PM
Jan-02-25 09:35AM
Jan-01-25 05:00AM
Dec-27-24 11:32AM
09:18AM
Dec-26-24 07:23AM
Dec-25-24 07:04AM
Dec-23-24 10:19AM
Dec-19-24 01:15PM
05:46AM
(Pharmaceutical Technology)
Dec-18-24 09:00AM
Dec-16-24 04:20PM
03:00AM
Dec-13-24 10:31AM
Dec-12-24 06:34PM
07:51PM
Loading…
Dec-09-24 07:51PM
09:28AM
07:41AM
Dec-07-24 06:34AM
Dec-06-24 04:35PM
(GlobeNewswire) +9.36%
-76.85%
Dec-05-24 04:30PM
Dec-04-24 04:47PM
Nov-21-24 04:30PM
Nov-12-24 11:01PM
Nov-07-24 04:30PM
(GlobeNewswire) -10.11%
+7.61%
Nov-04-24 09:00AM
Oct-24-24 09:00AM
Oct-21-24 10:53AM
Oct-17-24 09:45AM
Oct-12-24 02:31PM
Oct-07-24 09:10PM
Oct-05-24 07:15AM
Oct-03-24 09:05AM
Oct-01-24 04:30PM
Sep-26-24 04:08PM
(Investor's Business Daily)
02:36PM
08:25AM
Sep-25-24 08:00PM
04:13PM
11:27AM
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Richmond, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Pande Vijay Satyanand Director Oct 01 '24 Buy 19.73 126,793 2,501,626 1,026,793 Oct 03 07:19 PM Pande Vijay Satyanand Director Oct 02 '24 Buy 19.73 67,096 1,323,804 1,093,889 Oct 03 07:19 PM Pande Vijay Satyanand Director Oct 03 '24 Buy 19.90 25,306 503,589 1,119,195 Oct 03 07:19 PM Cormorant Asset Management, LP Former 10% Owner Sep 27 '24 Buy 18.00 450,000 8,100,000 1,629,529 Oct 01 04:01 PM Pande Vijay Satyanand Director Sep 27 '24 Buy 18.00 900,000 16,200,000 900,000 Sep 27 04:28 PM ENRIGHT PATRICK G Director Sep 27 '24 Buy 18.00 400,000 7,200,000 1,710,589 Sep 27 04:26 PM HEALY JAMES Director Sep 27 '24 Buy 18.00 666,665 11,999,970 2,227,124 Sep 27 04:22 PM
Index RUT P/E - EPS (ttm) - Insider Own 76.39% Shs Outstand 41.78M Perf Week 9.66%
Market Cap 327.22M Forward P/E - EPS next Y - Insider Trans 18.28% Shs Float 10.54M Perf Month -6.00%
Income - PEG - EPS next Q -0.99 Inst Own 32.27% Short Float 31.29% Perf Quarter -48.11%
Sales - P/S - EPS this Y - Inst Trans 29.04% Short Ratio 9.96 Perf Half Y -
Book/sh 8.60 P/B 0.91 EPS next Y - ROA - Short Interest 3.30M Perf Year -
Cash/sh 9.26 P/C 0.85 EPS next 5Y - ROE - 52W Range 5.83 - 26.25 Perf YTD -4.40%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -70.17% Beta -
Dividend TTM - Quick Ratio 8.95 Sales past 5Y 0.00% Gross Margin - 52W Low 34.31% ATR (14) 0.76
Dividend Ex-Date Dec 24, 2019 Current Ratio 8.95 EPS Y/Y TTM - Oper. Margin - RSI (14) 50.31 Volatility 10.70% 10.27%
Employees - Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 33.00
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q -21.88% Payout - Rel Volume 0.52 Prev Close 7.81
Sales Surprise - EPS Surprise -427.92% Sales Q/Q - Earnings Nov 12 BMO Avg Volume 331.03K Price 7.83
SMA20 6.37% SMA50 -6.52% SMA200 -41.90% Trades
Volume 172,236 Change 0.26%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-04-25 Initiated Wolfe Research
Outperform
$19
Dec-16-24 Initiated H.C. Wainwright
Buy
$30
Nov-05-24 Initiated Rodman & Renshaw
Buy
$34
Oct-08-24 Initiated Morgan Stanley
Overweight
$40
Oct-08-24 Initiated Jefferies
Buy
$35
Oct-08-24 Initiated Guggenheim
Buy
$45
Oct-08-24 Initiated Citigroup
Buy
$27
Feb-05-25 07:05AM
Jan-28-25 08:00AM
Dec-17-24 06:25AM
Dec-12-24 07:35AM
Nov-12-24 07:10AM
07:05AM
Loading…
07:05AM
Nov-07-24 07:05AM
Oct-14-24 06:45AM
Sep-19-24 04:15PM
Sep-13-24 04:09PM
12:19AM
Sep-12-24 10:37PM
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MOULDER LEON O JR Chief Executive Officer Feb 18 '25 Buy 6.67 25,000 166,750 266,155 Feb 19 04:01 PM Xiao Ting Director Feb 07 '25 Buy 7.76 10,000 77,600 47,000 Feb 11 04:20 PM MOULDER LEON O JR Chief Executive Officer Dec 04 '24 Buy 9.98 45,000 449,100 241,155 Dec 04 09:03 PM MOULDER LEON O JR Chief Executive Officer Dec 03 '24 Buy 10.76 25,000 269,000 196,155 Dec 04 09:03 PM MOULDER LEON O JR Chief Executive Officer Nov 18 '24 Buy 15.00 7,500 112,500 168,655 Nov 20 05:20 PM MOULDER LEON O JR Chief Executive Officer Nov 19 '24 Buy 14.57 2,500 36,425 171,155 Nov 20 05:20 PM MOULDER LEON O JR Chief Executive Officer Sep 18 '24 Buy 17.91 10,000 179,100 1,662,039 Sep 20 06:34 PM MOULDER LEON O JR Chief Executive Officer Sep 20 '24 Buy 18.45 5,000 92,270 1,672,039 Sep 20 06:34 PM MOULDER LEON O JR Chief Executive Officer Sep 19 '24 Buy 17.89 5,000 89,450 1,667,039 Sep 20 06:34 PM Enavate Sciences GP, LLC 10% Owner Sep 16 '24 Buy 17.00 882,353 15,000,001 3,761,359 Sep 18 04:15 PM Lu Hongbo Director Sep 13 '24 Buy 17.00 58,823 999,991 58,823 Sep 17 07:52 PM ENRIGHT PATRICK G Director Sep 16 '24 Buy 17.00 440,000 7,480,000 774,530 Sep 16 08:57 PM Nunn Jason Raleigh Director Sep 16 '24 Buy 17.00 882,352 14,999,984 1,946,564 Sep 16 08:54 PM Fairmount Funds Management LLC Director Sep 16 '24 Buy 17.00 300,000 5,100,000 1,604,891 Sep 16 08:54 PM SR ONE CAPITAL MANAGEMENT, LLC 10% Owner Sep 16 '24 Buy 17.00 2,235,294 37,999,998 1,946,564 Sep 16 08:51 PM
Index - P/E 19.59 EPS (ttm) 6.94 Insider Own 4.85% Shs Outstand 60.44M Perf Week -0.59%
Market Cap 8.22B Forward P/E 6.17 EPS next Y 22.03 Insider Trans -0.38% Shs Float 57.52M Perf Month 12.55%
Income 463.16M PEG 2.78 EPS next Q 5.81 Inst Own 98.27% Short Float 7.33% Perf Quarter 15.66%
Sales 3.99B P/S 2.06 EPS this Y 10.52% Inst Trans -0.33% Short Ratio 6.96 Perf Half Y 18.30%
Book/sh 69.01 P/B 1.97 EPS next Y 8.99% ROA 3.95% Short Interest 4.22M Perf Year 7.64%
Cash/sh 43.31 P/C 3.14 EPS next 5Y 7.05% ROE 12.09% 52W Range 99.06 - 138.27 Perf YTD 10.44%
Dividend Est. - P/FCF 7.28 EPS past 5Y -3.53% ROI 4.49% 52W High -1.63% Beta 0.47
Dividend TTM - Quick Ratio 3.74 Sales past 5Y 15.82% Gross Margin 73.85% 52W Low 37.30% ATR (14) 3.40
Dividend Ex-Date - Current Ratio 4.26 EPS Y/Y TTM 504.09% Oper. Margin 18.49% RSI (14) 68.46 Volatility 2.41% 2.60%
Employees 2800 Debt/Eq 1.49 Sales Y/Y TTM 5.23% Profit Margin 11.60% Recom 1.33 Target Price 184.22
Option/Short Yes / Yes LT Debt/Eq 1.47 EPS Q/Q 65.30% Payout 0.00% Rel Volume 0.95 Prev Close 136.65
Sales Surprise 1.78% EPS Surprise 20.22% Sales Q/Q 8.52% Earnings Feb 25 AMC Avg Volume 606.07K Price 136.01
SMA20 6.60% SMA50 9.19% SMA200 18.53% Trades
Volume 575,530 Change -0.47%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-13-25 Upgrade Wells Fargo
Equal Weight → Overweight
$130 → $170
Dec-12-24 Upgrade Morgan Stanley
Equal-Weight → Overweight
$140 → $175
Jun-05-24 Initiated Goldman
Buy
$169
Jan-03-24 Initiated Robert W. Baird
Outperform
$160
Nov-27-23 Downgrade UBS
Buy → Neutral
$170 → $135
Sep-29-23 Initiated Raymond James
Mkt Perform
Jun-12-23 Resumed Wells Fargo
Equal Weight
$184 → $140
Dec-09-22 Upgrade Goldman
Neutral → Buy
$192 → $190
Jun-14-22 Initiated UBS
Buy
$194
Apr-06-22 Downgrade Goldman
Buy → Neutral
$202 → $196
Nov-19-21 Resumed Goldman
Buy
$198
Oct-07-21 Resumed Jefferies
Buy
$172
Oct-05-21 Initiated Citigroup
Buy
$200
Sep-23-21 Initiated Needham
Buy
$220
May-19-21 Resumed JP Morgan
Overweight
$183 → $206
Apr-07-21 Resumed RBC Capital Mkts
Outperform
$186
Feb-05-21 Reiterated H.C. Wainwright
Buy
$195 → $207
Feb-03-21 Upgrade Piper Sandler
Neutral → Overweight
$150 → $175
Jan-29-21 Downgrade Morgan Stanley
Overweight → Equal-Weight
Dec-16-20 Initiated UBS
Buy
$174
Show Previous Ratings
Feb-20-25 04:15PM
09:15AM
Feb-12-25 09:25AM
Feb-11-25 04:15PM
Feb-05-25 12:10PM
01:57PM
Loading…
Jan-15-25 01:57PM
01:54PM
Dec-17-24 04:15PM
Dec-16-24 04:05PM
Dec-13-24 08:00AM
Dec-06-24 04:05PM
11:31AM
Dec-05-24 07:45AM
Dec-04-24 04:15PM
Dec-03-24 07:49AM
09:55AM
Loading…
Nov-29-24 09:55AM
Nov-28-24 05:50AM
Nov-22-24 06:36AM
Nov-20-24 07:19PM
Nov-19-24 04:05PM
09:40AM
08:29AM
Nov-18-24 08:30AM
Nov-14-24 08:46AM
Nov-13-24 12:00PM
09:55AM
Nov-11-24 12:29PM
09:15AM
Nov-08-24 05:00AM
Nov-07-24 07:22PM
(Morningstar Research) +6.75%
02:20AM
Loading…
02:20AM
Nov-06-24 07:00PM
05:55PM
04:49PM
(Associated Press Finance)
04:05PM
Nov-04-24 09:16AM
Oct-31-24 04:05PM
Oct-30-24 10:01AM
Oct-27-24 02:00AM
Oct-24-24 08:30AM
Oct-23-24 04:15PM
Oct-18-24 04:34PM
(Pharmaceutical Technology)
05:21AM
Oct-17-24 09:55AM
09:40AM
Oct-16-24 03:55PM
08:54AM
07:35AM
Oct-15-24 11:50AM
10:31AM
07:30AM
06:47AM
Oct-14-24 09:52AM
Oct-11-24 12:32PM
Oct-09-24 04:15PM
Oct-08-24 04:22AM
Oct-04-24 10:00AM
Oct-03-24 07:40AM
Oct-01-24 09:40AM
Sep-16-24 07:30AM
Sep-09-24 07:58AM
Sep-07-24 10:17PM
Sep-05-24 07:30AM
01:07AM
Sep-04-24 12:12AM
Sep-03-24 07:00AM
Sep-02-24 06:05PM
Aug-30-24 11:31AM
01:16AM
Aug-23-24 10:13AM
(Pharmaceutical Technology)
Aug-22-24 04:05PM
Aug-21-24 04:15PM
Aug-06-24 09:55AM
09:40AM
Aug-05-24 04:06PM
09:15AM
Jul-31-24 10:36PM
05:45PM
04:40PM
(Associated Press Finance)
04:05PM
Jul-29-24 06:00AM
Jul-25-24 04:05PM
Jul-24-24 10:01AM
Jul-23-24 03:52AM
Jul-22-24 07:45AM
Jul-19-24 01:58PM
Jul-17-24 04:15PM
Jul-11-24 08:30AM
Jul-09-24 07:45AM
Jul-04-24 08:09AM
Jul-01-24 12:16AM
Jun-26-24 02:11PM
Jun-25-24 03:39PM
Jun-21-24 07:00AM
06:33AM
Jun-20-24 04:08PM
(Investor's Business Daily)
10:08AM
(Investor's Business Daily)
07:45AM
Jun-14-24 06:13AM
Jun-11-24 10:42AM
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
COZADD BRUCE C Chairman & CEO Feb 03 '25 Sale 122.31 1,500 183,465 439,744 Feb 05 05:41 PM COZADD BRUCE C Officer Feb 03 '25 Proposed Sale 122.31 1,500 183,465 Feb 03 05:04 PM COZADD BRUCE C Chairman & CEO Jan 02 '25 Sale 123.43 1,500 185,145 425,525 Jan 06 04:22 PM COZADD BRUCE C Officer Jan 02 '25 Proposed Sale 123.43 1,500 185,145 Jan 02 05:00 PM COZADD BRUCE C Chairman & CEO Dec 02 '24 Sale 121.17 2,000 242,340 427,025 Dec 04 05:24 PM Carr Patricia SVP, Chief Accounting Officer Dec 02 '24 Sale 122.49 53 6,492 6,596 Dec 04 05:20 PM COZADD BRUCE C Officer Dec 02 '24 Proposed Sale 121.17 2,000 242,340 Dec 02 06:05 PM Carr Patricia Officer Dec 02 '24 Proposed Sale 122.49 53 6,492 Dec 02 04:20 PM Patil Neena M EVP & Chief Legal Officer Nov 08 '24 Sale 123.41 3,700 456,617 33,048 Nov 13 05:44 PM Patil Neena M Officer Nov 08 '24 Proposed Sale 123.41 3,700 456,632 Nov 08 05:55 PM COZADD BRUCE C Chairman & CEO Nov 01 '24 Sale 110.84 1,000 110,840 428,976 Nov 05 05:00 PM COZADD BRUCE C Officer Nov 01 '24 Proposed Sale 110.84 1,000 110,840 Nov 01 03:19 PM Henderson Mary Elizabeth SVP, Technical Operations Sep 06 '24 Sale 108.30 1,410 152,703 14,531 Sep 11 11:38 AM Henderson Mary Elizabeth Officer Sep 06 '24 Proposed Sale 110.00 2,691 296,010 Sep 05 07:50 PM Winningham Rick E Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:57 PM Smith Mark Douglas Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:55 PM RIEDEL NORBERT G Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:49 PM ORiordan Anne Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:42 PM O'Keefe Kenneth W Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:35 PM McSharry Heather Ann Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:29 PM Cook Jennifer E. Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:19 PM Sohn Catherine A. Director Aug 05 '24 Proposed Sale 111.00 3,075 341,325 Aug 02 04:20 PM Carr Patricia SVP, Chief Accounting Officer Jun 07 '24 Sale 108.83 163 17,738 6,596 Jun 11 08:15 PM Patil Neena M EVP & Chief Legal Officer May 03 '24 Sale 109.65 5,000 548,250 36,629 May 07 05:31 PM Carr Patricia SVP, Chief Accounting Officer Mar 06 '24 Sale 119.64 1,936 231,628 8,364 Mar 08 06:07 PM Carr Patricia SVP, Chief Accounting Officer Mar 07 '24 Sale 116.98 1,768 206,821 6,596 Mar 08 06:07 PM Johnson Philip L EVP & Chief Financial Officer Mar 01 '24 Buy 119.65 12,000 1,435,800 27,932 Mar 05 07:28 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
